Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (341-350 of 377) with videos related to

Pageof 38
Sort By:
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Cancers|October 14, 2022
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic ImplicationsMichele Simbolo, Giovanni Centonze, Luca Giudice, et al.
BMC Cancer|June 13, 2023
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN studyFilippo Lococo, Luca Boldrini, Charles-Davies Diepriye, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
European Journal of Cancer (Oxford, England : 1990)|March 30, 2020
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance statusFrancesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, et al.
Cancers|January 11, 2024
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA StudyMarina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, et al.
Pageof 38

Showing results (341-350 of 377) with videos related to

Sort By:
Pageof 38
Plos One|September 5, 2015
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast CancerStefania Gori, Alessandro Inno, Elena Fiorio, et al.
Cancers|October 14, 2022
Combined Large Cell Neuroendocrine Carcinomas of the Lung: Integrative Molecular Analysis Identifies Subtypes with Potential Therapeutic ImplicationsMichele Simbolo, Giovanni Centonze, Luca Giudice, et al.
BMC Cancer|June 13, 2023
Lung cancer multi-omics digital human avatars for integrating precision medicine into clinical practice: the LANTERN studyFilippo Lococo, Luca Boldrini, Charles-Davies Diepriye, et al.
Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.
La Radiologia Medica|July 7, 2026
Request and reporting models for computed tomography in the multidisciplinary management of cancer patients: consensus between the Italian Society of Medical and Interventional Radiology (SIRM) and the Italian Society of Medical Oncology (AIOM)Vincenza Granata, Alessandro Serafini, Roberta Fusco, et al.
Scientific Reports|December 8, 2015
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNiki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, et al.
Nature Communications|June 24, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world studyDavide Massa, Theodoros Foukakis, Sylvie Giacchetti, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
European Journal of Cancer (Oxford, England : 1990)|March 30, 2020
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance statusFrancesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, et al.
Cancers|January 11, 2024
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA StudyMarina Elena Cazzaniga, Paolo Pronzato, Domenico Amoroso, et al.
Pageof 38